Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-04-04 Declaration of Voting R…
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital) and explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF (Autorité des Marchés Financiers). It provides a table detailing the number of shares and voting rights as of March 31, 2024. This type of mandatory periodic disclosure in France, focusing purely on the total share capital and voting rights count, is a specific regulatory filing. It does not fit the definitions for Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). It is most closely related to notifications concerning share structure or major shareholdings, but the specific nature of reporting the total voting rights count aligns best with a specialized regulatory disclosure. Given the options, this is a specific regulatory announcement concerning capital structure/voting rights, which is often captured under general regulatory filings or specific share announcements. Since it is a formal, periodic disclosure mandated by financial regulators (AMF) detailing the total voting rights, it is a specific regulatory filing. While 'SHA' (Share Issue/Capital Change) is related, this document is a static report of the current count, not an announcement of a change or issue. 'MRQ' (Major Shareholding Notification) is for crossing thresholds, not the periodic total count. Therefore, 'RNS' (Regulatory Filings) serves as the most appropriate general category for this specific, mandatory regulatory disclosure that doesn't fit a more precise category like DIV or DIRS.
2024-04-04 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated April 2, 2024, announcing a business development milestone: the opening of the first Italian Center of Excellence for their Cellvizio product related to food intolerance testing. It includes quotes from the CEO and a doctor, and importantly, it contains a section titled "Prochaine publication financière" (Next financial publication) which schedules the release of the 'Annual 2023 financial results and Q1 2024 activity' for April 25, 2024. Since this document is an announcement about business operations and strategy, and not the financial results themselves, it is not an Earnings Release (ER) or an Interim Report (IR). It is a general corporate announcement. Furthermore, it is not a proxy statement (DEF 14A), a major shareholding notification (MRQ), or a director's dealing report (DIRS). Given its nature as a news update about strategic expansion and product adoption, and the fact that it is not a formal regulatory filing like a 10-K or a specific financial report, it best fits the general category of a Regulatory Filing (RNS) as a catch-all for important, non-standard announcements, or potentially an Investor Presentation (IP) if it were structured as a deck, but here it reads like a press release. Since it is a press release announcing operational news, and RNS is the fallback for general regulatory/corporate announcements not covered elsewhere, RNS is the most appropriate classification. It is not short enough to be a simple RPA.
2024-04-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated April 2, 2024, announcing a business development milestone: the opening of a Center of Excellence in Italy for a specific medical procedure (Cellvizio Food Intolerance Test). It details strategic expansion and includes quotes from the CEO and a specialist. Crucially, it contains a section titled 'Next financial release: Financial results Full Year 2023 and Trading Update Q1 2024, on April 25, 2024 after market close.' This structure—a news announcement about operations/partnerships, often released outside of mandated quarterly/annual filing windows—is characteristic of a general press release. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific regulatory filing like a Director's Dealing or Dividend Notice, and it is not merely announcing the publication of another report (RPA), the most appropriate classification is the general category for miscellaneous regulatory/corporate announcements, which is Regulatory Filings (RNS).
2024-04-02 English
Inside Information / Other news releases
M&A Activity Classification · 99% confidence The document is explicitly labeled as a "Press Release" and announces a strategic partnership between Mauna Kea Technologies and V7 to develop AI applications using the Cellvizio platform. It contains forward-looking statements and boilerplate information about both companies, typical of a corporate news announcement. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital event, falls best under the general category for regulatory announcements or news releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard corporate news releases that are publicly disseminated, although it is not a formal SEC filing. It is definitely not an AGM-R, 10-K, AR, CT, or ER. Since it is a press release announcing business developments rather than a specific financial report or mandatory filing, RNS is the most appropriate fallback.
2024-03-27 English
Informations privilégiées / Autres communiqués
M&A Activity Classification · 99% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a strategic partnership between Mauna Kea Technologies and V7 regarding AI development using the Cellvizio platform. It contains forward-looking statements and boilerplate information about both companies. This type of announcement, which is a general corporate update or news release that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), is best classified as a general Regulatory Filing or Announcement. Since it is a press release announcing a business development rather than a formal regulatory filing like a 10-K or a specific financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements. It is not a report itself, nor is it a proxy statement, dividend notice, or management discussion.
2024-03-27 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a strategic partnership between Mauna Kea Technologies and Metrodora Institute regarding the Cellvizio technology for food intolerance testing. It contains forward-looking statements and boilerplate information about both companies, typical of a corporate announcement intended for immediate public dissemination. This format strongly suggests a general regulatory announcement or press release rather than a formal, comprehensive financial filing like a 10-K, IR, or ER. Since it is a general corporate announcement that doesn't fit the specific categories (like M&A, Capital Change, Dividend, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (8870 chars) is substantial enough that it is not merely an announcement *about* a report (RPA), but the report itself (the press release).
2024-03-06 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.